Trials / Unknown
UnknownNCT03598348
Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer
Maintenance Treatment With Capecitabine Plus Apatinib vs. Apatinib and Observation After First-line XELOX/SOX Chemotherapy for Patients With Advanced Gastric Cancer: a Multicenter, Randomized, Controlled Trial
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 288 (estimated)
- Sponsor
- Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, controlled trial to evaluate the efficacy and safety of Maintenance Treatment with Capecitabine plus Apatinib, Apatinib and Observation after First-line XELOX/SOX chemotherapy for Patients with Advanced Gastric Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib+Capecitabine | Capecitabine 1000mg/m2 po bid, d1-14, Apatinib 250mg po Qd, Q21d |
| DRUG | Apatinib | Apatinib 250mg po Qd |
Timeline
- Start date
- 2018-01-16
- Primary completion
- 2020-01-16
- Completion
- 2020-10-16
- First posted
- 2018-07-26
- Last updated
- 2018-07-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03598348. Inclusion in this directory is not an endorsement.